Table 1.
n (%) | n1 (%) | n2 (%) | OR | 95% CI | P value | |
Interventional effect on clinical improvement | ||||||
Mild stroke | 283 (32.7) | 65 (63.1) | 496 (66.9) | 0.81 | 0.51 to 1.28 | 0.3554 |
Moderate stroke | 704 (39.5) | 122 (58.1) | 899 (59.3) | 1.23 | 0.71 to 2.13 | 0.4551 |
Severe stroke | 245 (30.4) | 59 (64.8) | 416 (66.1) | 1.12 | 0.58 to 2.17 | 0.7278 |
Interventional effect on sICH | ||||||
Mild stroke | 17 (1.97) | 4 (3.77) | 13 (1.71) | 2.71 | 0.80 to 7.69 | 0.1026 |
Moderate stroke | 59 (3.31) | 2 (0.94) | 57 (3.63) | 0.13 | 0.02 to 0.68 | 0.0159* |
Severe stroke | 71 (8.80) | 14 (13.3) | 57 (8.12) | 0.65 | 0.19 to 2.55 | 0.5180 |
Groups: mild: NIHSS 0–4; moderate: NIHSS 5–14; severe: NIHSS ≥15.
*P<0.05. Compared with those treated with standard dosage, patients treated with lower dosage of tPA have significantly less risk of sICH.
n1, number in low dose group; n2, number in standard dose group; n, total sample size in each group; NIHSS, National Institutes of Health Stroke Scale; sICH, symptomatic intracranial haemorrhage; tPA, tissue plasminogen activator.